EnglishGermanChinese (Simplified)FrenchJapanese

Alzheimer's Test

Did you know that 1/3 of the people with Minimal Cognitive Impairment (MCI) don’t get Alzheimer’s? The only way to find out for sure is through biomarker testing. 


Alzheimer's Test

Named the SYNTap™ Biomarker Test, this diagnostic test helps distinguish underlying synucleinopathies in Alzheimer’s Disease (AD). In short, it enables doctors to differentiate Alzheimer’s from other dementias.

Who should take the Alzheimer's Test?

  • If you have previously been diagnosed with Alzheimer’s, the SYNTap biomarker test enables your doctors to identify and differentiate mixed type dementias.

  • If your doctor suspects a neurodegenerative condition, you need this biomarker test to understand what role, if any, misfolded Synuclein plays.

  • If you have suspicions but have not been diagnosed with Alzheimer’s, this test helps your doctor complete a full workup.

What are the key benefits?

Alzheimer’s biomarker testing offers remarkable benefits, such as the following:

  • Enables physicians to differentiate Alzheimer’s from other brain diseases, matching the right patient with the right drug.
  • Ends the misery of misdiagnosis, which leads to drug mistreatment causing more harm than help,
  • Live a fuller, better quality of life through positive changes in diet, exercise, and sharing time with family and friends,
  • Participate in the right clinical trials with confidence,
  • Make life plans to navigate brain health journey, such as building a care team
  • Enrich science to accelerate innovation and find cures for the next generations!

Molecular diagnosis is the first step to personalized medicine for treating Alzheimer’s.

Why biomarker testing? Because accurate diagnosis saves lives!

The SYNTap Test identifies misfolded synuclein aggregates, a hallmark in synucleinopathy, enabling doctors to differentiate Alzheimer’s from other dementia.

misfolded protein synuclein
Why biomarker testing? Because accurate diagnosis saves lives! The SYNTap Test identifies misfolded synuclein aggregates, a hallmark in synucleinopathy, enabling doctors to differentiate Alzheimer’s from other dementia.

How does the Alzheimer's Test work?

After a decade of strenuous development in our lab, it’s quite simple now. Here’re three key steps: 

  1. Your doctor orders the test and submits a few drops of your cerebrospinal fluid (CSF),
  2. Our lab tests your sample for misfolded Synuclein,
  3. Your doctor receives the lab result within two weeks.

Click here to see this simple process illustrated in an infographic.

Why test CSF instead of blood?

CSF testing offers the highest accuracy, reliability, and EARLY detection. Why?

Because if misfolded proteins are detectable in blood, that means they have breached the blood-brain barrier and are spreading throughout the body.

Why is it crucial to differentiate Alzheimer's from LBD?

Alzheimer’s and Lewy Body Dementia are two distinct diseases with overlapping symptoms, especially in the early stages. 

The diseases take unique progression paths, therefore requiring different treatments.  Differentiating them matters greatly. 

Challenges to early-distinguish Alzheimer's vs. LBD

Here are some key points:

  • Initially, Alzheimer’s patients mainly show a cognitive decline such as loss of memory and executive functions. However, for advanced Alzheimer’s patients, motor symptoms may also appear.
  • Similarly, LBD patients first show comparable cognitive decline. They may also experience visual/olfactory hallucinations, dizziness, constipation, sleep disorders, etc.
  • Like Alzheimer’s, advanced LBD patients may also show motor symptoms, a hallmark of Parkinson’s.
  • The shared symptoms of Alzheimer’s and LBD are strikingly similar before the noticeable movement symptoms start. 

These mixed symptoms make Alzheimer’s and LBD nearly impossible to distinguish early based on clinical symptoms using traditional diagnostics methods.

Harmful consequences of misdiagnosis

Brain diseases are notoriously difficult to track and treat due to the nasty characteristics of misfolded proteins (aka prions). Misidentifying prions results in detrimental treatment side effects.

Simply put, Alzheimer’s drugs may harm LBD patients and vice versa. Here are three examples:

  • Memantine, a drug commonly used to treat moderate to severe Alzheimer’s, may worsen both cognitive and motor symptoms in LBD patients.
  • Antipsychotic medications used to treat behavioral disorders in Alzheimer’s patients can cause serious side effects in LBD patients.
  • Levodopa, an LBD medication, has little or no cognitive benefit when given to Alzheimer’s patients and may even induce or worsen motor disorders.

Prescribing proper drugs for the right disease makes precise early-stage diagnosis even more critical. 

Because with the wrong drugs, the patient suffers more harmful consequences. 

Comparing Alzheimer's and LBD biomarkers

  • LBD results from the proliferation of misfolded Synuclein protein aggregates in the brain. Misfolded Synuclein causes both cognitive and motor symptoms in LBD patients.
  • In Alzheimer’s, cognitive decline arises from the accumulation of two types of misfolded brain proteins: Abeta and Tau.
  • In advanced Alzheimer’s, patients may also develop Parkinson’s-like motor symptoms.
  • These late-stage Alzheimer’s symptoms are associated with misfolded Synuclein or TDP43, another misfolded protein biomarker.
  • So in neurodegenerative disorders, four biomarkers drive disease progression: Misfolded forms of Synuclein, Abeta, Tau, and TDP43. 

Did you know brain diseases are often misdiagnosed? 
Conservatively estimated up to 50%! Let’s END that.

parkinson's research and care center

Did you know brain diseases are often misdiagnosed? 
Conservatively estimated up to 50%! Let’s END that.

Alzheimer's Biomarkers

The following misfolded protein biomarkers are always present in Alzheimer’s patients at all stages:

  • Abeta
  • Tau

Furthermore, two other misfolded protein biomarkers appear in advanced Alzheimer’s patients: 

  • Synuclein
  • TDP43

Each misfolded protein type causes distinct damage to brain cells. The insidious nature of prions makes Alzheimer’s diagnosis immensely challenging. It has been this way since Dr. Alois Alzheimer first described the condition in 1906.

Therefore, to completely diagnose what’s driving Alzheimer’s, all four biomarker tests are required.   


This diagnostic test identifies misfolded Synuclein, a prion protein present in many brain diseases years before symptoms. Sign up to receive information about the test.

Share this great news with someone you love! 💖

Scroll to Top
Share on facebook
Share on twitter
Share on linkedin